Equities Analysts Offer Predictions for EPRX FY2026 Earnings

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) – Lifesci Capital dropped their FY2026 earnings per share estimates for shares of Eupraxia Pharmaceuticals in a research report issued to clients and investors on Monday, March 16th. Lifesci Capital analyst S. Slutsky now forecasts that the company will post earnings per share of ($0.88) for the year, down from their previous estimate of ($0.75). Lifesci Capital currently has a “Strong-Buy” rating on the stock. The consensus estimate for Eupraxia Pharmaceuticals’ current full-year earnings is ($0.67) per share.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) last posted its earnings results on Thursday, March 19th. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.16) by ($0.21).

Several other research analysts have also recently issued reports on EPRX. HC Wainwright lowered their target price on shares of Eupraxia Pharmaceuticals from $12.00 to $11.00 and set a “buy” rating for the company in a report on Tuesday. Zacks Research lowered shares of Eupraxia Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Tuesday. Weiss Ratings reissued a “sell (d-)” rating on shares of Eupraxia Pharmaceuticals in a research report on Thursday, January 22nd. Wall Street Zen downgraded shares of Eupraxia Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, February 21st. Finally, Cantor Fitzgerald raised their price objective on Eupraxia Pharmaceuticals from $11.00 to $19.00 and gave the stock an “overweight” rating in a report on Thursday, January 15th. Two investment analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, Eupraxia Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $15.00.

Eupraxia Pharmaceuticals Stock Down 6.6%

Shares of Eupraxia Pharmaceuticals stock opened at $7.10 on Thursday. Eupraxia Pharmaceuticals has a 52 week low of $2.68 and a 52 week high of $9.32. The firm’s 50 day moving average is $8.26 and its two-hundred day moving average is $6.89. The firm has a market capitalization of $255.32 million, a P/E ratio of -6.89 and a beta of 1.27.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of EPRX. Royal Bank of Canada grew its holdings in shares of Eupraxia Pharmaceuticals by 21.1% during the first quarter. Royal Bank of Canada now owns 342,828 shares of the company’s stock worth $1,125,000 after buying an additional 59,683 shares during the last quarter. JPMorgan Chase & Co. boosted its stake in shares of Eupraxia Pharmaceuticals by 593.2% in the second quarter. JPMorgan Chase & Co. now owns 18,717 shares of the company’s stock valued at $108,000 after buying an additional 16,017 shares in the last quarter. Quadrature Capital Ltd acquired a new position in Eupraxia Pharmaceuticals during the second quarter worth $61,000. Bank of America Corp DE grew its holdings in Eupraxia Pharmaceuticals by 402.4% during the second quarter. Bank of America Corp DE now owns 12,559 shares of the company’s stock worth $72,000 after acquiring an additional 10,059 shares during the period. Finally, TCI Wealth Advisors Inc. purchased a new position in Eupraxia Pharmaceuticals in the third quarter worth $65,000.

Trending Headlines about Eupraxia Pharmaceuticals

Here are the key news stories impacting Eupraxia Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright reiterated a “Buy” rating and maintained an $11 price target, which provides upside support for the stock despite the earnings cuts — MarketBeat EPRX Coverage
• Neutral Sentiment: Brokers published predictions ahead of EPRX’s Q2 earnings, adding near-term expectations but not reporting any definitive catalyst; this keeps near-term guidance uncertainty elevated. Brokers Offer Predictions for EPRX Q2 Earnings
• Neutral Sentiment: A short-interest report in the period shows effectively zero reported short interest (data appears anomalous), so short covering is unlikely to be a near-term price driver.
• Negative Sentiment: Zacks downgraded Eupraxia from “Hold” to “Strong Sell,” a formal negative signal that likely pressured the shares. Zacks Downgrade
• Negative Sentiment: HC Wainwright cut multiple near- and multi‑year EPS forecasts (FY2026–FY2029 and Q1/Q3 2026), materially lowering profitability outlooks even while keeping a Buy rating — this mix of lower forecasts and unchanged optimism may create investor skepticism. HC Wainwright Estimates
• Negative Sentiment: Lifesci Capital trimmed its FY2026 EPS forecast (now deeper negative), which adds to the consensus downside revisions despite Lifesci retaining a “Strong-Buy” stance.

Eupraxia Pharmaceuticals Company Profile

Eupraxia Pharmaceuticals, Inc (NASDAQ: EPRX) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for autoimmune and inflammatory diseases. The company’s core strategy centers on selectively expanding regulatory T cells (Tregs)—immune cells responsible for maintaining self-tolerance and limiting pathological inflammation—through its proprietary platform. Its lead therapeutic candidate is currently in Phase 1 clinical development in patients with systemic lupus erythematosus.

Based in Seattle, Washington, Eupraxia Pharmaceuticals conducts research and development activities across North America, collaborating with academic institutions and contract research organizations to advance its pipeline.